OMED OncoMed Pharmaceuticals Inc.

4.61
-0.02  -0%
Previous Close 4.63
Open 4.63
Price To book -3.22
Market Cap 173476342
Shares 37,630,443
Volume 130,563
Short Ratio 4.86
Av. Daily Volume 195,924

SEC filingsSee all SEC filings

  1. 8-K - Current report 171091136
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000111
  3. 8-K - Current report 17999913
  4. 8-K - Current report 17958092
  5. CT ORDER - Confidential treatment order 17903179

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released April 10, 2017 - primary endpoint not met.
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Announced November 1, 2016 that it has discontinued further enrollment. Phase 2 data released May 8, 2017 - endpoints not met.
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2 data released April 17, 2017 - primary endpoint not met.
Tarextumab - PINNACLE trial
Small cell lung cancer
Company announced late January 2016 that they plan to unblind the trial following notice from the DSMB that suggests a low likelihood of a statistically significant benefit in overall survival. Subsequently, in February 2016 an announcement was made to discontine the trial
Tarextumab ALPINE
Pancreatic Cancer